Biopharmx Corp (NYSE:BPMX) gained ground Tuesday, after the company announced that its Phase 2b trial of BPX-04 for Populopustular Rosacea met both primary and secondary endpoints and was well tolerated
The San Jose-based, BioPharmX, a specialty pharmaceutical company focused on developing innovative medical dermatology products, announced positive results from its Phase 2b clinical trial of BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea.
Rosacea is a long-term skin condition that typically affects the face.
BPX-04, a 1% minocycline gel, successfully met both the primary and secondary endpoints of the trial in demonstrating a statistically significant mean change in the number of facial inflammatory lesions and a two-grade improvement to clear or almost clear on the Investigator's Global Assessment (IGA) scale from baseline to week 12.
Said CEO David Tierney, "We are extremely pleased with the positive outcome on both the primary and secondary efficacy measures as well as the confirmation of the safety and cutaneous tolerability of our minocycline gel formulation.”
"The study was designed to demonstrate a statistically significant mean change in the number of facial inflammatory lesions from baseline to week 12.
The secondary endpoint, the proportion of subjects with a two-grade improvement to clear or almost clear on the IGA scale from baseline to week 12, was included to collect sufficient data to design a Phase 3 program with co-primary efficacy endpoints, however, as is standard in a Phase 2 trial, the study was not designed to demonstrate statistical significance on the secondary endpoint.
Shares gained seven cents, or 7.8%, to 95 cents.
